This trial is evaluating whether Liver Machine Perfusion (MP) device will improve 2 primary outcomes and 10 secondary outcomes in patients with Transplantation, Liver. Measurement will happen over the course of up to 36 weeks.
This trial requires 15 total participants across 1 different treatment group
This trial involves a single treatment. Liver Machine Perfusion (MP) Device is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are not being studied for commercial purposes.
"Transplants, transplants of liver are the most common treatments for liver diseases. And also, it's an important issue that the immunosuppressives are often administated for transplants." - Anonymous Online Contributor
"Patients with end-stage liver disease with or without significant extrahepatic B cell disease could receive successful immunosuppressive treatment and potentially receive a potential cure by liver transplantation." - Anonymous Online Contributor
"Patients who develop liver disease have an identifiable change in their health status in the weeks before presentation to the transplant unit. They have jaundice, vomiting or weakness. They have either increased fatigue or malaise and have a higher degree of jaundice with a bilirubin level of >50 µl/l. Patients who have developed graft-versus-host disease can be identified by symptoms including chills, chest pain, shortness of breath and an unfavourable chest X-ray. Patients may have had leukopenia when they are admitted to hospital. They also have a leukocytosis when they are presenting to the transplant unit. These are all signs of liver disease." - Anonymous Online Contributor
"Liver transplants were first performed in Boston during the late 1940s. The liver is the largest and most complex organ in the human body and is transplanted in approximately 100,000 cases every year in the United States and Europe. Liver transplantation is a procedure that is usually carried out to help patients who lack a functioning organ or who have an organ that no longer performs its normal function. In most cases the recipient of a liver transplant will live an essentially normal life and go on to have happy, productive lives." - Anonymous Online Contributor
"[More than one-third (34%), or about 600,000 people in the United States are transplanted each year for acute-on-chronic liver disease or cirrhosis, respectively.] It is estimated that the number of patients receiving donor liver transplants will reach an all-time high of approximately 2 million by 2050. About 90% of these are patients who previously were categorized as being on the continuum between the U.S. population and the population in countries where the world's liver transplant population is concentrated. In addition, the number of patients who might be eligible for living donor transplantation is far less than the number transplanted. Only a fraction of these chronically ill patients may be eligible for either transplantation or other alternative therapies." - Anonymous Online Contributor
"Liver cirrhosis has a complex multifactorial cause. Primary liver disease is a risk factor which is further affected by alcoholism and cirrhosis of other regions (i.e. portal hypertension, hyperactive liver disease and/or hepatic encephalopathy). Hepatitis viral or non-host viral infection can cause cirrhosis as well. Alcoholics and patients of HIV are at a higher risk. Non-specific and more specific factors include a family history of liver disease, viral load and HCV. Transplantation related factors include age of recipient, transplant type (i.e. deceased donor vs living donor, HLA mismatch." - Anonymous Online Contributor
"Recent advances in transplantation treatment may change these current guidelines. With the recent developments in transplants, we are approaching transplantation as a key component of a new multidisciplinary approach to transplant medicine. Continued clinical and translational research for transplant patients, with a focus on the prevention and treatment of acute rejection, as well as on improving kidney and liver function, will continue to evolve and lead to improvements in survival and quality of life, not only for the transplanted population but also for transplanted patients and their families." - Anonymous Online Contributor
"The fact that the families for whom LTx were considered are those who have a positive score indicates that this is a familial pattern of liver disease. The clinical presentation is also very similar to the familial presentation. The clinical and serological features in the first degree relatives have no significative different to the main patients and therefore are not sufficient to justify the exclusion of family screening. Findings from a recent study suggests that the prevalence of autoimmune liver disease in familial pattern in the general population is significant and must be studied before introducing LTx in this group." - Anonymous Online Contributor
"Liver machine perfusion may provide safe, effective, and durable treatment for some liver diseases, such as, liver injuries, liver transplantation, and acute liver failure. As to hepatic tumor, liver machine perfusion treatment may be a helpful technique for patients with hepatic tumors." - Anonymous Online Contributor
"Liver machine perfusion (mp) device, including the newest designs, has proven safety and efficacy in the treatment of many cirrhotic patients. Our machine perfusion device, which is made by a French device, has shown to increase the blood recovery of the liver to nearly normal levels in the group of transplanted patients. The treatment is simple, and requires minimal equipment. The machine perfusion technique in our hepatic machines was patented by Dr. M. Chatterjea; and the machines were registered in the Netherlands under a Belgian Law. We have now developed a new modular system for MP, which should increase the reliability of the blood and blood products recovery of the patient through a liver machine perfusion technique." - Anonymous Online Contributor
"By using Power-SEM site, we can find clinical trials that can help you find your optimal liver transplant. After doing some simple filtering criteria, you will find a great deal of good clinical trial to start with. It may be a good place for [inhibition therapy] for your patient." - Anonymous Online Contributor
"Our modified Liver Machine Perfusion (LMP) system had a good capacity for resuscitation and extended graft survival during warm ischemia. We hope that this may translate to good clinical results in patients undergoing elective orthotopic liver transplantation." - Anonymous Online Contributor